Renal Transporter‐Mediated Drug‐Biomarker Interactions of the Endogenous Substrates Creatinine and N1‐Methylnicotinamide: A PBPK Modeling Approach. Issue 3 (7th June 2022)

• Record Type: Journal Article
• Authors: Türk, Denise; Müller, Fabian; Fromm, Martin F.; Selzer, Dominik; Dallmann, Robert; Lehr, Thorsten
• Is Part Of: Clinical pharmacology & therapeutics. Volume 112:Issue 3(2022)
• Page Start: 687
• Page End: 698
• Publication Date: 2022-06-07
• Subjects: Pharmacology -- Periodicals; Therapeutics -- Periodicals; 615.5
• DOI: 10.1002/cpt.2636
• Languages: English
• ISSNs: 0009-9236

Abstract

Abstract : Endogenous biomarkers for transporter‐mediated drug‐drug interaction (DDI) predictions represent a promising approach to facilitate and improve conventional DDI investigations in clinical studies. This approach requires high sensitivity and specificity of biomarkers for the targets of interest (e.g., transport proteins), as well as rigorous characterization of their kinetics, which can be accomplished utilizing physiologically‐based pharmacokinetic (PBPK) modeling. Therefore, the objective of this study was to develop PBPK models of the endogenous organic cation transporter (OCT)2 and multidrug and toxin extrusion protein (MATE)1 substrates creatinine and N 1 ‐methylnicotinamide (NMN). Additionally, this study aimed to predict kinetic changes of the biomarkers during administration of the OCT2 and MATE1 perpetrator drugs trimethoprim, pyrimethamine, and cimetidine. Whole‐body PBPK models of creatinine and NMN were developed utilizing studies investigating creatinine or NMN exogenous administration and endogenous synthesis. The newly developed models accurately describe and predict observed plasma concentration‐time profiles and urinary excretion of both biomarkers. Subsequently, models were coupled to the previously built and evaluated perpetrator models of trimethoprim, pyrimethamine, and cimetidine for interaction predictions. Increased creatinine plasma concentrations and decreased urinary excretion during the drug‐biomarker interactions with trimethoprim, pyrimethamine, and cimetidine were well‐described. An additional inhibition of NMN synthesis by trimethoprim and pyrimethamine was hypothesized, improving NMN plasma and urine interaction predictions. To summarize, whole‐body PBPK models of creatinine and NMN were built and evaluated to better assess creatinine and NMN kinetics while uncovering knowledge gaps for future research. The models can support investigations of renal transporter‐mediated DDIs during drug development.